Clinical Trial

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Protocol Amendment History 2 changes
notable Trial sites expanded: 61 -> 75 locations 2026-07-29
notable Trial sites expanded: 40 -> 61 locations 2026-05-29
Trial Details
NCT Number NCT07022483
Lead Sponsor Daiichi Sankyo
Collaborators: AstraZeneca
Conditions Endometrial Cancer
Enrollment 710 participants
Start Date 2025-09-30
Primary Completion 2032-03-23 (estimated)
Study Completion 2032-03-23 (estimated)
Updated on ClinicalTrials.gov 2026-07-28